secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0000950170-25-029510
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M
--------------------------------------------------------------------------------

- Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.
- GAAP net loss of $42.7M ($1.41 per share) for FY 2024; non-GAAP income $15.0M ($0.49 per share).
- Q4 2024 total revenue $76.2M; core revenue up 14% to $76.0M; GAAP loss $5.9M, non-GAAP income $1.2M.
- Ended 2024 with $828.6M cash & investments ($26.87/share); cash from ops $21.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017025029510/0000950170-25-029510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017025029510/flgt-20250228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer